The pathophysiology and optimal management of thyroid eye disease (TED) have not yet been elucidated. Recent studies have increased our knowledge of the disease process and different diagnostic and therapeutic options. This review highlights the recent progress in TED research and identifies areas requiring further advancements.
Introduction
Thyroid eye disease (TED), also called thyroid-associated ophthalmopathy (TAO) and Graves' ophthalmopathy/orbitopathy, is the most common orbital disease, affecting 25-50% of patients with Graves' disease [1] . Clinical symptoms and signs are usually mild, consisting of ocular irritation with redness and tearing, 'stare' due to lid retraction and exophthalmos, and periorbital swelling. Approximately 28% of TED cases are severe, with restricted motility leading to diplopia, exposure keratopathy, and optic neuropathy [2, 3 ] . Patients with severe TED may have lower rates of remission of their thyroid disease compared with mild TED patients [4 ] . Despite ongoing basic science and clinical research, highly effective therapeutic strategies remain elusive.
Pathophysiology
In TED, the dramatically enlarged extraocular muscles and increased orbital fat result from a complex interplay among orbital fibroblasts, immune cells, cytokines, autoantibodies, genetics, and environmental factors [1] . However, clear and indisputable identification of a target antigen has not been established.
Autoimmunity
Lehmann et al.
[5 ] summarized a plausible pathway for fibroblast activation in TED. They stated that 'According to one current model, TED is triggered by binding and activation of orbital fibroblasts by autoantibodies. These autoantibodies could be specific for antigens such as TSH-R and/or IGF-1R. Activated orbital fibroblasts release chemokines, including IL-16,RANTES, and CXCL10, which recruit T lymphocytes into the orbit. These lymphocytes then interact with fibroblasts, potentially activating each other, further promoting cytokine production (IFNg, TNF a , PGD 2 , and 15d-PGJ 2 ) and secretion of T-cell-activating factors by the fibroblasts (IL-8 and CXCL10). Fibroblasts are also stimulated to secrete IL-6 (promoting B-cell differentiation) and to increase autoantigen presentation, both of which amplify the overall response. The interactions of fibroblasts with T cells result in the deposition of extracellular matrix molecules, fibroblast proliferation, and fat accumulation' (Fig. 1 ).
In this scenario, autoantibodies specific for fibroblast surface thyroid-stimulating hormone receptor (TSH-R) and insulin-like growth factor-1 receptor (IGF-1R) are proposed initiators of orbital inflammation [1, 5 ] . However, increased TSH-R and IGF-1R expression occur with adipogenesis, providing an alternative, noncausative explanation for their presence in TED orbits [1, 6] .
Autoantibody stimulation activates fibroblasts to release chemokines and cytokines, promoting lymphocyte migration and B-cell maturation [5 ] . Interaction with humoral and cell-mediated elements of the immune system through orbital fibroblast surface CD40 and human leukocyte antigen-DR (HLA-DR) may lead to increased autoantigen presentation and further release of cytokines. Prostaglandin E 2 (PGE 2 ), interleukin (IL)-6, and IL-8 may act on orbital fibroblasts to promote proliferation and production of glycosaminoglycans (GAGs), increasing extraorbital muscle mass. Prostaglandin D 2 (PGD 2 ) and 15-deoxy-D 12,14-prostaglandin J 2 (15d-PGJ 2 ) may act on an orbital fibroblast transcription factor called peroxisome proliferator-activated receptor-g (PPARg), leading to orbital fibroblast adipogenesis and increased orbital fat. Cyclooxygenase-2 (COX-2) expressed by orbital fibroblasts increases synthesis of the involved prostaglandins. Vondrichova et al. [7 ] demonstrated that COX-2 and stearoyl-coenzyme A desaturase (SCD), an adipose tissue marker, are overexpressed in orbital tissue from TED patients with active, compared with chronic, disease.
In cocultures, autologous T lymphocytes stimulate TED orbital fibroblast proliferation [8] . Chen et al.
[9 ] demonstrated that there is more infiltration of macrophages and higher mRNA levels of a macrophage chemoattractant called C-C motif chemokine ligand-2 (CCL2)/monocyte chemoattractant protein-1 (MCP-1) in the orbital fat compared with normal controls.
Smoking
Cigarette smoking is a risk factor for the development and severity of TED [1]. Cawood et al.
[10 ] established that orbital fibroblasts exposed to cigarette smoke extract 500 Ocular manifestations of systemic disease Figure 1 Pathophysiology of thyroid eye disease GAG, glycosaminoglycans; IFN-g, interferon-g; IGF, insulin-like growth factor-1; MHC, major histocompatibility complex; PGD 2 , prostaglandin D 2 ; PGJ 2 , prostaglandin J 2 ; PPARg, peroxisome proliferator-activated receptor-g; RANTES, Regulated on Activation Normal T Cell Expressed and Secreted; TCR, T-cell receptor; TNF, tumor necrosis factor; TSH, thyroid-stimulating hormone. Adapted from [5 ].
(CSE) had a dose-dependent statistically significant increase in GAG production and adipogenesis. Moreover, IL-1 and CSE had a synergistic effect on adipogenesis.
Genetics
Bednarczuk et al.
[11 ] cited conflicting evidence from case-control studies examining the association between TED and genes involved in inflammation, such as HLA, cytotoxic T-lymphocyte antigen-4 (CTLA-4), tumor necrosis factor (TNF), interferon-g (IFN-g), intercellular adhesion molecule-1 (ICAM-1), and TSH-R. On the basis of these investigations, either a unifying polymorphism has yet to be identified or TED has a multifactorial inheritance pattern.
Syed et al. [12 ] found an association between mild/ moderate TED and certain single nucleotide polymorphisms (SNPs) in the protein tyrosine phosphatase (PTP) called PTPN12, which interacts with the TSH-R, the proposed target of autoantibodies in Graves' disease. Furthermore, SNPs in the proinflammatory IL-23 receptor, which affects T lymphocyte phenotype, were shown to be significantly associated with TED by Huber et al.
[13 ].
Nuclear factor (NF)-kB1, a transcription regulator, is activated by several stimuli, including cytokines. Polymorphisms of NF-kB1 are associated with several chronic inflammatory and autoimmune diseases [14 ] . Kurylowicz et al.
[14 ] established a correlation between a polymorphism in the NF-kB1 gene promoter (-94ins/ del adenine, thymine, thymine, guanine ) and the development and age of onset of TED within a Japanese cohort.
Chong et al.
[15 ] found a positive trend between an IL-13 SNP (2044G/A) and the development of proptosis in a study population of Chinese children. Boyle et al. [16 ] demonstrated that certain polymorphisms that confer hypersensitivity of the glucocorticoid receptor, which has an anti-inflammatory effect, were associated with less severe TED. Akaishi et al.
[17 ] studied the frequency of the class II major histocompatibility complex (MHC) HLA alleles in 81 Brazilian TED patients and 161 normal controls. TED patients with major extraocular muscle involvement were found to have a higher frequency of the HLA-DRB1Ã16 allele, whereas patients with minor extraocular muscle involvement were found to have a higher frequency of the HLA-DRB1Ã03 allele.
Clinical research
Diagnostic techniques, standardized scoring systems, psychological impact assessment, as well as pharmacological and surgical therapies are areas of clinical TED research.
Diagnostic testing modalities
Majos et al.
[18 ] studied magnetic resonance imaging (MRI) of 40 orbits to examine the correlation between extraocular muscle volume and the measurement of signal intensity and T2-time (T2-t), which they considered indicators of inflammation. Both signal intensity and T2-t were found to have statistically significant correlations with volumes of most of the extraocular muscles. This study did not directly correlate the findings of T2-t and signal intensity with clinical symptoms.
Using digital infrared thermal imaging to diagnose early TED, Chang et al.
[19 ] studied 32 control orbits and 28 TED orbits. They found a significantly increased temperature among the TED orbits. A positive correlation was noted between the severity of TED and temperature. In addition, a significant decrease in the temperature was found after pulse methylprednisone therapy.
Another tool to measure orbital inflammation is the uptake of radioactively labeled substances, such as 67 gadolinium (Ga) citrate and 99m technetium (Tc)labeled agents [20 ] . Reyhan et al. [20 ] prospectively studied the use of 99m Tc(V)-dimercaptosuccinic acid [99mTc(V)-DMSA] in 28 TED patients and found a significant correlation between uptake of the agent and clinical activity score (CAS). Another study by Sun et al.
[21 ] demonstrated a correlation between 99m Tc-hydrazinonicotinic (HYNIC)-octreotide uptake and CAS in 14 TED patients. This study also showed a significant difference in orbital/occipital uptake ratio between TED patients who were responders to retrobulbar irradiation and those who were not.
Clinical classification systems
Severity scores assess TED in a standardized fashion and are especially important in clinical trials. Two such scoring systems are the so-called modified NOSPECS (No signs or symptoms; Only signs; Soft tissue involvement with symptoms and signs; Proptosis; Eye muscle involvement; Corneal involvement; Sight loss) and the CAS systems [22, 23] . The modified NOSPECS criteria include lid retraction, soft tissue inflammation, proptosis, size difference, extraocular muscle involvement, corneal defects, and optic nerve compression [23] . The CAS includes pain, redness, swelling, and impaired visual function, which may signal acute inflammation [22] . Both measure symptom severity. [24] included subjective and objective components combining aspects of NOSPECS and CAS, with subjective input from the patient about how they feel about their TED status. The so-called VISA classification includes Vision (presence or absence of optic neuropathy), Inflammation (0-8 or mild, mod-erate, or severe), Strabismus (0-3), restriction (0-3), and Appearance/exposure (mild, moderate, or severe). In future studies, scoring systems should be compared directly to purported objective measures of inflammation, such as the MRI signal intensity and T2-t, thermography, and the radioactive uptake studies described previously.
Dolman and Rootman

Psychological and quality of life impact
Disfigurement and visual changes of TED have a large impact on patients' psychological state and quality of life (QOL). Bradley et al. [25] examined the use of the National Eye Institute Visual Function Questionnaire (NEI VQF-25) to assess the effect of TED on QOL in a 30-patient cross-sectional study. Moderate impairments were found in the Mental Health and Role Difficulties categories. However, two-thirds of patients felt the questionnaire was not appropriate to assess the impact of TED. Estcourt et al. [26 ] noted development of altered identity in taped, semistructured interviews of 25 TED patients.
Treatment trials
Variation in presentation of TED symptoms and signs, as well as difficulty in assessing autoimmune activity, complicates study design. Obstacles include small sample sizes, as well as heterogeneity of response to anti-inflammatory and immunomodulatory therapy. [32 ] performed a systematic review of nine randomized controlled trials and five observational studies with more than 100 patients on the use of orbital radiation as a treatment for TED. On the basis of the randomized controlled trials, orbital radiation yielded no improvement in proptosis, eyelid retraction, or soft tissue changes. Radiation retinopathy occurred in 1-2% of patients. There was conflicting evidence from the randomized controlled trials regarding the improvement of ocular motility, and the one study that examined effect of orbital radiation on QOL had inconclusive findings. However, a metaanalysis by Wei et al. [33 ] , which included data from eight cohort studies and 10 randomized controlled trials, found that orbital radiation was more effective than a vehicle control and as effective as steroids alone. The use of combined corticosteroids and orbital radiation varied in the studies reviewed by Bradley et al. [32 ] . Wei et al. [33 ] found radiation and steroid combination therapy to be more effective than either used alone. Zoumalan et al.'s [28 ] observations were similar.
New immunomodulation therapies
Etanercept, which has an extracellular binding site for TNFa, an inflammatory cytokine, decreases the level of biologically active TNFa [34] . Possible side effects include infections, malignancies, and the development of additional autoimmune disorders [34] .
Paridaens et al. [34] performed a pilot study using biweekly 25 mg etanercept subcutaneous injections for 12 weeks in 10 euthyroid, recent onset TED patients with a mean pretreatment CAS of 4 (range: 3-6). Mean CAS decreased to 2.6 at 6 weeks and 1.6 at 12 weeks [34] . No toxicity was noted.
Rituximab is a monoclonal antibody directed against CD20, a B lymphocyte surface antigen [35 ] . Possible adverse reactions with rituximab include infusion reaction, serum sickness, and increased infections. Targeting B cells should theoretically eventually dampen the inflammatory process in TED [35 ] .
Salvi et al. [36] reported a steroid refractory case of TED with improvement of CAS after rituximab treatment and no histological evidence of lymphocyte infiltrate in orbital tissue removed during decompression surgery. However, a pilot study of Graves' disease patients comparing rituximab and methimazole with methimazole monotherapy by El Fassi et al. [35 ] found no difference in TSH-R antibody levels between the groups.
Rapamycin is an antibiotic in the macrolide class, which also inhibits cytokines and growth factor-mediated proliferation of fibroblasts and immune cells [37 ] . Possible adverse reactions associated with rapamycin include myelosuppression (most often thrombocytopenia) and hyperlipidemia.
Chang et al. [37 ] reported a case of TED with dysthyroid optic neuropathy that was refractory to steroids and decompression surgery but improved gradually when treated with rapamycin in conjunction with prednisone taper. The patient developed hyperlipidemia during rapamycin treatment.
Surgical therapy
TED surgeries may relieve acute optic nerve compression in dysthyroid optic neuropathy and effectively mitigate the sequelae of chronic orbital inflammation.
Orbital decompression
Exophthalmos and apical compression of the optic nerve are indications for orbital decompression involving bone. In a study by Jernfors et al. [38 ] , 76% of patients felt that the surgery was very helpful. There was minimal improvement in diplopia and late complications included sinusitis (18%), oroantral fistula (3%), sensory disturbances (32%), facial neuralgia (13%), operation-induced diplopia (8%), and vision loss (3%). When comparing the complications (except operation-induced diplopia) with normal, matched controls, only sensory disturbances occurred significantly more frequently.
Fat removal orbital decompression removes orbital contents rather than accommodating them within a larger socket. Richter et al. [39 ] performed a retrospective study of transpalpebral fat removal orbital decompression on 1374 patients and found a decreased mean proptosis of 5.9 mm, improved symmetry of eye protrusion, improved visual acuity, and improvement in QOL (data unpublished). There were no cases of diplopia postoperatively. Wu et al.
[40 ] performed fat removal orbital decompression on 222 orbits in Taiwan and found a mean postoperative reduction of proptosis by Hertel measurement of 3.6 mm (range: 1.5-7.5, SD: 1.0) and improved diplopia in 20% (three out of 15) of patients with preoperative diplopia. Only 2.8% (three out of 105) of patients developed diplopia postoperatively.
Extraocular muscle surgery
Thomas and Cruz [41 ] , based on previous studies, reported the success rate of extraocular muscle surgery in TED varies from 43 to 82%. Controversy exists as to whether surgical decision making should be based upon reducing restriction of involved muscles or the degree of deviation between the eyes. In a study of 137 TED patients by Nguyen et al. [42] , a higher success rate and lower reoperation rate was found when correcting for the restricted duction compared with deviation. Dal Canto et al. [43] confirmed the success of this method in a more recent study of 24 TED patients. On the contrary, Thomas and Cruz [41 ] found no significant difference in the rate of successful outcomes in a retrospective study of 86 patients comparing the two approaches (P ¼ 0.55). Yan and Zhang [44 ] retrospectively studied 27 TED patients with large angle strabismus (>258) and found that 74% (20/27) of cases were successfully treated with single extraocular muscle recession, suggesting that for the majority of large angle strabismus, single extraocular muscle surgery is adequate.
Medical and surgical recommendations
On behalf of a European consortium studying TED, Bartalena et al. [45 ] published the set of medical and surgical recommendations shown in Fig. 2 where they stated that 'Rehabilitative surgery includes orbital decompression, squint surgery, lid lengthening, and blepharoplasty/browplasty'. They felt that joint management by endocrinology and ophthalmology was optimal. Although many of their suggestions such as cessation of smoking and ocular surface management are common practice, their advocacy of i.v. steroids and orbital radiation is controversial and requires further study.
In the absence of highly efficacious anti-inflammatory or immunomodulatory therapy, our approach to management of TED is to use conservative measures directed toward patient comfort for mild-to-moderate disease. Artificial tears, nocturnal lid taping, elevating the head of the bed, and occasional use of diuretics are often sufficient in the active stage. Chronic soft tissue alterations are treated surgically. Severe TED, particularly when accompanied by optic neuropathy, is managed using high-dose oral prednisone. If full taper cannot be achieved within 2 months, then bony orbital decompression is performed. Orbital radiation is considered an adjunct to steroids, decompression, or both for recalcitrant disease. Immunosuppressive and immunomodulatory drugs are not generally utilized.
Future directions
Understanding the autoimmunity of TED is crucial to improve patient management, especially during active disease. Unfortunately, there are neither accepted biomarkers associated with 'active' TED, nor are there biomarkers predictive of developing severe disease. Drugs that could suppress early, active TED all have substantial side effects. Therefore, in the absence of predictive diagnostic or clinical signs, the risk:benefit ratio of treatment may be adverse. Furthermore, many of the inflammatory symptoms and signs may reflect consequences rather than causes of disease. For instance, ocular surface exposure and compartment syndrome may produce substantial nonspecific inflammation partially responsive to anti-inflammatory therapy. Antifibrotic agents may prove more effective than immune suppressant therapy late in the disease process.
Questionnaires designed to assess autoimmune inflammatory activity must be validated against objective measures of inflammation. In the future, blood tests looking at inflammatory markers of TED may prove highly beneficial in planning therapy. Soluble CD40, CD154, vascular cell adhesion molecule-1, and matrix metalloproteinase-9 or urine tests for oxidative stress, such as urinary 8-OHdG levels, are possible examples [46 -48 ] .
Conclusion
Great strides have been made over the last year in many aspects of TED research, especially regarding the pathophysiology of TED, assessment of inflammatory activity, and novel uses of immunomodulating therapies. New medical and surgical management options have been introduced. Also, traditional therapies have been further studied. Much research remains to be done in the field of TED pathophysiology in order to provide insight regarding risk factors, targets for therapy, and the ideal window for anti-inflammatory versus antifibrotic treatments. Large, prospective, randomized, controlled clinical trials must be designed around proper assessment of patients' inflammatory status. These studies will lead to a consensus regarding management of TED. A study of the difference in levels of COX-2 and SCD gene expression in orbital adipose/connective tissue between acute and chronic phase TED patients demonstrated increased levels of COX-2 and SCD gene expression among acute phase patients. Diclofenac, a COX-2 inhibitor and PPARg antagonist, reduced adipogenesis in vitro and requires further study. A study of the effects of CSE AE IL-1 on ICAM-1, GAG production, and adipogenesis in orbital tissue from 10 TED patients and nine controls. The authors found a dose-dependent relationship between CSE and both GAG production and adipogenesis but no effect on ICAM-1 expression. Furthermore, IL-1 and CSE had a synergistic effect on adipogenesis, which was reduced by 81% with an anti-IL-1 antibody. The authors suggest IL-1 as a possible therapeutic target.
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